With the acquisition of Robocath completed, Stereotaxis intends to accelerate development of next-generation robotic technologies for endovascular procedures.
Source: MedTech Dive
You may also like
My Search for a Psychiatric Bed in an Overburdened...
J&J wins FDA approval for dual-energy ablation...
Physicians’ wearable data use hampered by...
Resmed to sell MatrixCare for $490M to private equity...
CVS CEO says Aetna has a handle on medical costs in...
Whistleblower lawsuit accuses Alignment of accounting...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.